<DOC>
	<DOCNO>NCT00330330</DOCNO>
	<brief_summary>The aim study evaluate safety , tolerability , pharmacokinetics five ISIS 113715 intravenous dose cohort drug-na√Øve type 2 diabetic .</brief_summary>
	<brief_title>Safety , Tolerability , Activity ISIS 113715 People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 Diabetes Mellitus le 5 year duration Have never receive hypoglycemic therapy Aged 18 65 year Fasting blood glucose 130 220 mg/dL ( 7.2 12.2 mmol/L ) Cohorts AD 140 220 mg/dL ( 7.8 12.2 mmol/L ) Cohort E HbA1c 6.8 10.0 % Cohorts AD 7.5 11.0 % Cohort E Body Mass index &gt; 25 &lt; 35 kg 2 Medication may affect glucose homeostasis ( e.g . systemic glucocorticoid ) within one month screen Clinically significant abnormality medical history physical exam Clinically significant abnormality laboratory examination History HIV infection Active infection require antiviral antimicrobial therapy Malignancy ( exception basal squamous cell carcinoma skin adequately treat recurrence &gt; one year time screen ) Any concurrent condition , opinion Investigator , would preclude participation interfere compliance Alcohol drug abuse Undergoing undergone treatment another investigational drug , biologic agent device within 90 day screen Abnormal serum creatinine concentration define &gt; 1.5 mg/dL ( 132.6 micro mol/L ) males &gt; 1.2 mg/dL ( 106 micro mol/L ) females Medications may affect coagulation ( heparin , warfarin , etc . ) exception acetylsalicylic acid nonsteroidal antiinflammatory agent . Allergy sulfurcontaining medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Fasting plasma glucose</keyword>
	<keyword>HbA1c</keyword>
</DOC>